Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MMP12 | P39900 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29893671 | 0.84 | PKM (0.59) | PKMSMN1; SMN2MMP12LMNAPARP1 | |
| SCHEMBL30197829 | 0.84 | SMN1; SMN2 (0.62) | PKMSMN1; SMN2MMP12LMNAPARP1 | |
| SCHEMBL707711 | 0.84 | SMN1; SMN2 (0.62) | PKMSMN1; SMN2MMP12LMNAPARP1 | |
| SCHEMBL1970405 | 0.84 | PKM (0.59) | PKMSMN1; SMN2MMP12LMNAPARP1 | |
| SCHEMBL707964 | 0.84 | PKM (0.59) | PKMSMN1; SMN2MMP12LMNAPARP1 | |
| SCHEMBL706059 | 0.82 | PARP1 (0.62) | PKMSMN1; SMN2MMP12LMNAPARP1 | |
| SCHEMBL4261435 | 0.82 | NR3C2 (0.54) | PKMSMN1; SMN2MMP12LMNAPARP1 | |
| SCHEMBL13932061 | 0.82 | NR3C2 (0.54) | PKMSMN1; SMN2MMP12LMNAPARP1 | |
| SCHEMBL10154038 | 0.81 | SMN1; SMN2 (0.69) | PKMSMN1; SMN2MMP12LMNAPARP1 | |
| SCHEMBL20364687 | 0.81 | SMN1; SMN2 (0.58) | PKMSMN1; SMN2MMP12LMNAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134403-A1 | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | Incyte Corporation (US) | 2017-03-01 | — | — | EP | claimed |
| WO-2015164480-A1 | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | INCYTE CORPORATION (US) | 2015-10-29 | — | — | WO | claimed |
| EP-2511264-B1 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8426422-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2511264-A1 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2387560-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8042193-B1 | Systems and methods for controlling data access by use of a universal anonymous identifier | Albright Associates (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100184750-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010083441-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184750-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | PKM 4645/4885SMN1; SMN2 2848/4885MMP12 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.